Ion channels are progressively emerging as a novel class of membrane proteins expressed in several types of human cancers and regulating the different aspects of cancer cell behavior. The metabolism of cancer cells, usually composed by a variable proportion of respiration, glycolysis, and glutaminolysis, leads to the excessive production of acidic metabolic products. The presence of these acidic metabolites inside the cells results in intracellular acidosis, and hinders survival and proliferation. For this reason, tumor cells activate mechanisms of pH control that produce a constitutive increase in intracellular pH (pHi) that is more acidic than the extracellular pH (pHe). This condition forms a perfect microenvironment for metastatic progression and may be permissive for some of the acquired characteristics of tumors. Recent analyses have revealed complex interconnections between oncogenic activation, ion channels, hypoxia signaling and metabolic pathways that are dysregulated in cancer. Here, we summarize the molecular mechanisms of the Warburg effect and hypoxia and their association. Moreover, we discuss the recent findings concerning the involvement of ion channels in various aspects of the Warburg effect and hypoxia, focusing on the role of Na+ and K+ channels in hypoxic and metabolic reprogramming in cancer.
Get full access to this article
View all access options for this article.
References
1.
HanahanD, WeinbergRA. Hallmarks of cancer: The next generation. Cell, 2011; 144:646–674.
2.
RobeyRB, WeiszJ, KuemmerleNB, et al.Metabolic reprogramming and dysregulated metabolism: Cause, consequence and/or enabler of environmental carcinogenesis?. Carcinogenesis, 2015; 36Suppl 1:S203–S231.
3.
PavlovaNN, ThompsonCB. The emerging hallmarks of cancer metabolism. Cell Metab, 2016; 23:27–47.
4.
SunL, SuoC, LiST, et al.Metabolic reprogramming for cancer cells and their microenvironment: Beyond the Warburg Effect. Biochim Biophys Acta Rev Cancer, 2018; 1870:51–66.
5.
LibertiMV, LocasaleJW. The warburg effect: How does it benefit cancer cells?. Trends Biochem Sci, 2016; 41:211–218.
6.
AlmuhaidebA, PapathanasiouN, BomanjiJ. 18F-FDG PET/CT imaging in oncology. Ann Saudi Med, 2011; 31:3–13.
7.
GilliesRJ, RobeyI, GatenbyRA. Causes and consequences of increased glucose metabolism of cancers. J Nucl Med, 2008; 49:24S–42S.
8.
Vander HeidenMG, CantleyLC, ThompsonCB. Understanding the Warburg effect: The metabolic requirements of cell proliferation. Science, 2009; 324:1029–1033.
9.
GatenbyRA, GilliesRJ. Why do cancers have high aerobic glycolysis?. Nat Rev Cancer, 2004; 4:891–899.
10.
AltenbergB, GreulichK. Genes of glycolysis are ubiquitously overexpressed in 24 cancer classes. Genomics, 2004; 84:1014–1020.
11.
PedersenSF, StockC. Ion channels and transporters in cancer: Pathophysiology, regulation, and clinical potential. Cancer Res, 2013; 73:1658–1661.
12.
JakabM, RitterM. Cell volume regulatory ion transport in the regulation of cell migration. Contrib Nephrol, 2006; 152:161–180.
13.
LangF, FöllerM, LangK, et al.Cell volume regulatory ion channels in cell proliferation and cell death. Methods Enzymol, 2007; 428:209–225.
14.
LeanzaL, ManagòA, ZorattiM, et al.Pharmacological targeting of ion channels for cancer therapy: In vivo evidences. Biochim Biophys Acta, 2016; 1863(6 Pt B):1385–1397.
15.
ArcangeliA, CrocianiO, LastraioliE, et al.Targeting ion channels in cancer: A novel frontier in antineoplastic therapy. Curr Med Chem, 2009; 16:66–93.
16.
Diaz-RuizR, RigouletM, DevinA. The Warburg and Crabtree effects: On the origin of cancer cell energy metabolism and of yeast glucose repression. Biochim Biophys Acta, 2011; 1807:568–576.
17.
WarburgO. On the origin of cancer cells. Science, 1956; 123:309–314.
18.
FadakaA, AjiboyeB, femiOjoO, et al.Biology of glucose metabolization in cancer cells. J Oncol Sci, 2017; 3:45–51.
19.
RathmellJC, FoxCJ, PlasDR, et al.Akt-directed glucose metabolism can prevent Bax conformation change and promote growth factor-independent survival. Mol Cell Biol, 2003; 23:7315–7328.
20.
VogelsteinB, KinzlerKW. Cancer genes and the pathways they control. Nat Med, 2004; 10:789–799.
21.
BarthelA, OkinoST, LiaoJ, et al.Regulation of GLUT1 gene transcription by the serine/threonine kinase Akt1. J Biol Chem, 1999; 274:20281–20286.
22.
WiemanHL, WoffordJA, RathmellJC. Cytokine stimulation promotes glucose uptake via phosphatidylinositol-3 kinase/Akt regulation of Glut1 activity and trafficking. Mol Biol Cell, 2007; 18:1437–1446.
23.
DeprezJ, VertommenD, AlessiDR, et al.Phosphorylation and activation of heart 6-phosphofructo-2-kinase by protein kinase B and other protein kinases of the insulin signaling cascades. J Biol Chem, 1997; 272:17269–17275.
24.
GottlobK, MajewskiN, KennedyS, et al.Inhibition of early apoptotic events by Akt/PKB is dependent on the first committed step of glycolysis and mitochondrial hexokinase. Genes Dev, 2001; 15:1406–1418.
25.
LastraioliE, BenciniL, BianchiniE, et al.hERG1 Channels and Glut-1 as independent prognostic indicators of worse outcome in stage I and II colorectal cancer: A Pilot Study. Transl Oncol, 2012; 5:105–112.
26.
JacksonJG, O'DonnellJC, KrizmanE, et al.Displacing hexokinase from mitochondrial voltage-dependent anion channel (VDAC) impairs GLT-1-mediated glutamate uptake but does not disrupt interactions between GLT-1 and mitochondrial proteins. J Neurosci Res, 2015; 93:999–1008.
27.
QiD, HeJ, WangD, et al.17β-estradiol suppresses lipopolysaccharide-induced acute lung injury through PI3K/Akt/SGK1 mediated up-regulation of epithelial sodium channel (ENaC) in vivo and in vitro. Respir Res, 2014; 15:159.
28.
KoehlGE, SpitznerM, OusingsawatJ, et al.Rapamycin inhibits oncogenic intestinal ion channels and neoplasia in APCMin/+ mice. Oncogene, 2010; 29:1553–1560.
29.
HanX, WangF, YaoW. Heat shock proteins and p53 play a critical role in K+ channel-mediated tumor cell proliferation and apoptosis. Apoptosis, 2007; 12:1837.
30.
Dhar-ChowdhuryP, HarrellMD, HanSY, et al.The glycolytic enzymes, glyceraldehyde-3-phosphate dehydrogenase, triose-phosphate isomerase, and pyruvate kinase are components of the K(ATP) channel macromolecular complex and regulate its function. J Biol Chem, 2005; 280:38464–38470.
31.
YingH, KimmelmanAC, LyssiotisCA, et al.Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell, 2012; 149:656–670.
32.
JiangP, DuW, WangX, et al.p53 regulates biosynthesis through direct inactivation of glucose-6-phosphate dehydrogenase. Nat Cell Biol, 2011; 13:310–316.
33.
ItkonenHM, MinnerS, GuldvikIJ, et al.O-GlcNAc transferase integrates metabolic pathways to regulate the stability of c-MYC in human prostate cancer cells. Cancer Res, 2013; 73:5277–5287.
34.
SpiroRG. Protein glycosylation: Nature, distribution, enzymatic formation, and disease implications of glycopeptide bonds. Glycobiology, 2002; 12:43R–56R.
35.
WellenKE, LuC, MancusoA, et al.The hexosamine biosynthetic pathway couples growth factor-induced glutamine uptake to glucose metabolism. Genes Dev, 2010; 24:2784–2799.
36.
LocasaleJW, GrassianAR, MelmanT, et al.Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis. Nat Genet, 2011; 43:869–874.
37.
PossematoR, MarksKM, ShaulYD, et al.Functional genomics reveal that the serine synthesis pathway is essential in breast cancer. Nature, 2011; 76:346–350.
38.
TibbettsAS, ApplingDR. Compartmentalization of Mammalian folate-mediated one-carbon metabolism. Annu Rev Nutr, 2010; 30:57–81.
NilssonR, JainM, MadhusudhanN, et al.Metabolic enzyme expression highlights a key role for MTHFD2 and the mitochondrial folate pathway in cancer. Nat Commun, 2014; 5:3128.
41.
NoguchiT, InoueH, TanakaT. The M1- and M2-type isozymes of rat pyruvate kinase are produced from the same gene by alternative RNA splicing. J Biol Chem, 1986; 261:13807–13812.
42.
ChristofkHR, Vander HeidenMG, HarrisMH, et al.The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature, 2008; 452:230–233.
43.
ChanetonB, HillmannP, ZhengL, et al.Serine is a natural ligand and allosteric activator of pyruvate kinase M2. Nature, 2012; 491:458–462.
44.
ChristofkHR, Vander HeidenMG, WuN, et al.Pyruvate kinase M2 is a phosphotyrosine-binding protein. Nature, 2008; 452:181–186.
45.
YeJ, MancusoA, TongX, et al.Pyruvate kinase M2 promotes de novo serine synthesis to sustain mTORC1 activity and cell proliferation. Proc Natl Acad Sci U S A, 2012; 109:6904–6909.
46.
LuntSY, Vander HeidenMG. Aerobic glycolysis: Meeting the metabolic requirements of cell proliferation. Annu Rev Cell Dev Biol, 2011; 27:441–464.
47.
WahlströmT and HenrikssonMA. Impact of MYC in regulation of tumor cell metabolism. Biochim Biophys Acta, 2015; 1849:563–569.
48.
PateKT, StringariC, Sprowl-TanioS, et al.Wnt signaling directs a metabolic program of glycolysis and angiogenesis in colon cancer. EMBO J, 2014; 33:1454–1473.
49.
KimJ, TchernyshyovI, SemenzaGL, et al.HIF-1-mediated expression of pyruvate dehydrogenase kinase: A metabolic switch required for cellular adaptation to hypoxia. Cell Metab, 2006; 3:177–185.
50.
PapandreouI, CairnsRA, FontanaL, et al.HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. Cell Metab, 2006; 3:187–197.
51.
MuzB, De la PuenteP, AzabF, et al.The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy. Hypoxia (Auckl), 2015; 3:83–92.
52.
SemenzaGL, WangGL. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol, 1992; 12:5447–5454.
53.
WangGL, JiangBH, RueEA, et al.Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA, 1995; 92:5510–5514.
54.
MaxwellPH, WiesenerMS, ChangGW, et al.The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature, 1999; 20; 399:271–275.
55.
YamashitaK, DischerDJ, HuJ, et al.Molecular regulation of the endothelin-1 gene by hypoxia. Contributions of hypoxia-inducible factor-1, activator protein-1, GATA-2, and p300/CBP. J Biol Chem, 2001; 276:12645–12653.
56.
ManaloDJ, RowanA, LavoieT, et al.Transcriptional regulation of vascular endothelial cell responses to hypoxia by HIF-1. Blood, 2005; 105:659–669.
UnwithS, ZhaoH, HennahL, et al.The potential role of HIF on tumour progression and dissemination. Int J Cancer, 2015; 136:2491–2503.
59.
SchmidT, ZhouJ, BrüneB. HIF-1 and p53: Communication of transcription factors under hypoxia. J Cell Mol Med, 2004; 8:423–431.
60.
McNeillLA, HewitsonKS, ClaridgeTD, et al.Hypoxia-inducible factor asparaginyl hydroxylase (FIH-1) catalyses hydroxylation at the beta-carbon of asparagine-803. Biochem J, 2002; 367(Pt 3):571–575.
61.
KoivunenP, HirsiläM, GünzlerV, et al.Catalytic properties of the asparaginyl hydroxylase (FIH) in the oxygen sensing pathway are distinct from those of its prolyl 4-hydroxylases. J Biol Chem, 2004; 279:9899–9904.
62.
ShetaEA, TroutH, GildeaJJ, et al.Cell density mediated pericellular hypoxia leads to induction of HIF-1alpha via nitric oxide and Ras/MAP kinase mediated signaling pathways. Oncogene, 2001; 20:7624–7634.
63.
ZundelW, SchindlerC, Haas-KoganD, et al.Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev, 2000; 14:391–396.
64.
BlancherC, MooreJW, RobertsonN, et al.Effects of ras and von Hippel-Lindau (VHL) gene mutations on hypoxia-inducible factor (HIF)-1alpha, HIF-2alpha, and vascular endothelial growth factor expression and their regulation by the phosphatidylinositol 3'-kinase/Akt signaling pathway. Cancer Res, 2001; 61:7349–7355.
65.
PoreN, JiangZ, ShuHK, et al.Akt1 activation can augment hypoxia-inducible factor-1alpha expression by increasing protein translation through a mammalian target of rapamycin-independent pathway. Mol Cancer Res, 2006; 4:471–479.
66.
EalesKL, HollinsheadKE, TennantDA. Hypoxia and metabolic adaptation of cancer cells. Oncogenesis, 2016; 5:e190.
67.
TennantDA. PK-M2 makes cells sweeter on HIF1. Cell, 2011; 145:647–649.
68.
GodaN, KanaiM. Hypoxia-inducible factors and their roles in energy metabolism. Int J Hematol, 2012; 95:457–463.
69.
MartiniveP, DefresneF, BouzinC, et al.Preconditioning of the tumor vasculature and tumor cells by intermittent hypoxia: Implications for anticancer therapies. Cancer Res, 2006; 66:11736–11744.
70.
DenkoNC. Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nat Rev Cancer, 2008; 8:705–713.
71.
UllahMS, DaviesAJ, HalestrapAP. The plasma membrane lactate transporter MCT4, but not MCT1, is up-regulated by hypoxia through a HIF-1alpha dependent mechanism. J Biol Chem, 2006; 281:9030–9037.
72.
MeijerTW, KaandersJH, SpanPN, et al.Targeting hypoxia, HIF-1, and tumor glucose metabolism to improve radiotherapy efficacy. Clin Cancer Res, 2012; 18:5585–5594.
73.
DownieBR, SánchezA, KnötgenH, et al.Eag1 expression interferes with hypoxia homeostasis and induces angiogenesis in tumors. J Biol Chem, 2008; 283:36234–36240.
74.
CrocianiO, ZanieriF, PillozziS, et al.hERG1 channels modulate integrin signaling to trigger angiogenesis and tumor progression in colorectal cancer. Sci Rep, 2013; 3:3308.
75.
IommariniL, PorcelliAM, GasparreG, et al.Non-canonical mechanisms regulating hypoxia-inducible factor 1 Alpha in Cancer. Front Oncol, 2017; 7:286.
76.
MazureNM, ChenEY, YehP, et al.Oncogenic transformation and hypoxia synergistically act to modulate vascular endothelial growth factor expression. Cancer Res, 1996; 56:3436–3440.
77.
AlmendrosI, GozalD. Intermittent hypoxia and cancer: Undesirable bed partners?. Respir Physiol Neurobiol, 2018; 256:79–86.
78.
AndersenAP, MoreiraJMA, PedersenSF. Interactions of ion transporters and channels with cancer cell metabolism and the tumour microenvironment. Philos Trans R Soc Lond B Biol Sci, 2014; 369:20130098.
79.
LastraioliE, IorioJ, ArcangeliA. Ion channel expression as promising cancer biomarker. Biochim Biophys Acta, 2015; 1848(10 Pt B):2685–2702.
80.
SontheimerH. An unexpected role for ion channels in brain tumor metastasis. Exp Biol Med (Maywood), 2008; 233:779–791.
81.
LangF. Mechanisms and significance of cell volume regulation. J Am Coll Nutr, 2007; 26(5 Suppl):613S–623S.
82.
BlackistonDJ, McLaughlinKA, LevinM. Bioelectric controls of cell proliferation: Ion channels, membrane voltage and the cell cycle. Cell Cycle, 2009; 8:3527–3536.
83.
PerrinMJ, SubbiahRN, VandenbergJI, et al.Human ether-a-go-go related gene (hERG) K+ channels: Function and dysfunction. Prog Biophys Mol Biol, 2008; 98:137–148.
84.
KunzelmannK. Ion channels and cancer. J Membr Biol, 2005; 205:159–173.
85.
RogerS, GilletL, LeJY et al. Voltage-gated sodium channels and cancer: Is excitability their primary role?. Front Pharmacol, 2015; 6:152.
86.
FraserSP, DissJK, ChioniAM et al. Voltage-gated sodium channel expression and potentiation of human breast cancer metastasis. Clin Cancer Res, 2005; 11:5381–5389.
87.
BrackenburyWJ, ChioniAM, DissJK, et al.The neonatal splice variant of Nav1.5 potentiates in vitro invasive behaviour of MDA-MB-231 human breast cancer cells. Breast Cancer Res Treat, 2007; 101:149–160.
88.
DissJK, StewartD, PaniF, et al.A potential novel marker for human prostate cancer: Voltage-gated sodium channel expression in vivo. Prostate Cancer Prostatic Dis, 2005; 8:266–273.
89.
LaniadoME, LalaniEN, FraserSP, et al.Expression and functional analysis of voltage-activated Na+ channels in human prostate cancer cell lines and their contribution to invasion in vitro. Am J Pathol, 1997; 150:1213–1221.
90.
BlandinoJK, ViglioneMP, BradleyWA, et al.Voltage-dependent sodium channels in human small-cell lung cancer cells: Role in action potentials and inhibition by Lambert-Eaton syndrome IgG. J Membr Biol, 1995; 143:153–163.
91.
OnganerPU, DjamgozMBA. Small-cell lung cancer (human): Potentiation of endocytic membrane activity by voltage-gated Na+ channel expression. J Membr Biol, 2005; 204:67–75.
92.
DiazD, DelgadilloDM, Hernández-GallegosE, et al.Functional expression of voltage-gated sodium channels in primary cultures of human cervical cancer. J Cell Physiol, 2007; 210:469–478.
93.
GuzelRM, OgmenK, IlievaKM, et al.Colorectal cancer invasiveness in vitro: Predominant contribution of neonatal Nav1.5 under normoxia and hypoxia. J Cell Physiol, 2019; 234:6582–6593.
94.
FulgenziG, GraciottiL, FaronatoM, et al.Neoplastic mesothelial cells express voltage-gated sodium channels involved in cell motility. Hum Int J Biochem Cell Biol, 2006; 38:1146–1159.
CampbellTM, MainMJ, FitzgeraldEM. Functional expression of the voltage-gated Na+-channel Nav1.7 is necessary for EGF-mediated invasion in human non-small cell lung cancer cells. J Cell Sci, 2013; 126(Pt 21):4939–4949.
97.
FiskeJL, FominVP, BrownML, Voltage-sensitive ion channels and cancer. Cancer Metastasis Rev, 2006; 25:493–500.
98.
PardoLA, StühmerW. The roles of K(+) channels in cancer. Nat Rev Cancer, 2014; 14:39–48.
99.
Rodríguez-RasgadoJA, Acuña-Macías I and CamachoJ. Eag1 channels as potential cancer biomarkers. Sensors, 2012; 12:5986–5995.
100.
DingXW, WangXG, LuoHS et al. Expression and Prognostic Roles of Eag1 in resected esophageal squamous cell carcinomas. Digest Dis Sci, 2008; 53:2039–2044.
101.
CherubiniA, TaddeiGL, CrocianiO, et al.HERG potassium channels are more frequently expressed in human endometrial cancer as compared to non-cancerous endometrium. Br J Cancer, 2000; 83:1722–1729.
102.
LastraioliE, GuastiL, CrocianiOet al.herg1 gene and HERG1 protein are overexpressed in colorectal cancers and regulate cell invasion of tumor cells. Cancer Res, 2004; 64:606–611.
103.
LastraioliE, TaddeiA, MesseriniL, et al.hERG1 channels in human esophagus: Evidence for their aberrant expression in the malignant progression of Barrett's esophagus. J Cell Physiol, 2006; 209:398–404.
104.
LastraioliE, PerroneG, SetteA, et al.hERG1 channels drive tumour malignancy and may serve as prognostic factor in pancreatic ductal adenocarcinoma. Br J Cancer, 2015; 112:1076–1087.
105.
AsherV, KhanR, WarrenA, et al.The Eag potassium channel as a new prognostic marker in ovarian cancer. Diagn Pathol, 2010; 5:78.
106.
MasiA, BecchettiA, Restano-CassuliniR, et al.hERG1 channels are overexpressed in glioblastoma multiforme and modulate VEGF secretion in glioblastoma cell lines. Br J Cancer, 2005; 93:781–792.
107.
PillozziS, BrizziMF, BalziM. HERG potassium channels are constitutively expressed in primary human acute myeloid leukemias and regulate cell proliferation of normal and leukemic hemopoietic progenitors. Leukemia, 2002; 16:1791–1798.
108.
SmithGAM, TsuiHW, NewellEW et al. Functional Up-regulation of HERG K+ channels in neoplastic hematopoietic cells. J Biol Chem, 2002; 277:18528–18534.
109.
MuratoriL, PetroniG, AntonuzzoL, et al.hERG1 positivity and Glut-1 negativity identifies high-risk TNM stage I and II colorectal cancer patients, regardless of adjuvant chemotherapy. Onco Targets Ther, 2016; 9:6325–6332.
110.
LastraioliE, LottiniT, IorioJ, et al.hERG1 behaves as biomarker of progression to adenocarcinoma in Barrett's esophagus and can be exploited for a novel endoscopic surveillance. Oncotarget, 2016; 7:59535–59547.
111.
CrocianiO, LastraioliE, BoniL, et al.hERG1 channels regulate VEGF-A secretion in human gastric cancer: Clinicopathological correlations and therapeutical implications. Clin Cancer Res, 2014; 20:1502–1512.
112.
GlassmeierG, HempelK, WulfsenI. Inhibition of HERG1 K+ channel protein expression decreases cell proliferation of human small cell lung cancer cells. Pflugers Arch, 2012; 463:365–376.
113.
AbdulM, HooseinN. Reduced Kv1.3 potassium channel expression in human prostate cancer. J Membr Biol, 2006; 214:99–102.
114.
BrevetM, AhidouchA, SevestreH, et al.Expression of K+ channels in normal and cancerous human breast. Histol Histopathol, 2008; 23:965–972.
115.
JangSH, KangKS, RyuPD, et al.Kv1.3 voltage-gated K(+) channel subunit as a potential diagnostic marker and therapeutic target for breast cancer. BMB Rep, 2009; 42:535–539.
116.
WangR, CaiB, XiangJ, et al.Expression of voltage-gated potassium channel Kv3.4 in oral squamous cell carcinoma. Zhonghua Kou Qiang Yi Xue Za Zhi, 2016; 51:137–142.
117.
PariharAS, GroebeDR, ScottVE, et al.Functional analysis of large conductance Ca2(+)-activated K(+) channels: Ion flux studies by atomic absorption spectrometry. Assay Drug Dev Technol, 2003; 1:647–654.
118.
JägerH, DrekerT, BuckA, et al.Blockage of intermediate-conductance Ca2+-activated K+ channels inhibit human pancreatic cancer cell growth in vitro. Mol Pharmacol, 2004; 65630–638.
119.
GuilbertA, Dhennin-DuthilleI, EL HianiY, et al.Expression of TRPC6 channels in human epithelial breast cancer cells. BMC Cancer, 2008; 8:125.
120.
WeaverAK, BombenVC, SontheimerH, et al.Expression and function of calcium-activated potassium channels in human glioma cells. GLIA, 2006; 54:223–233.
121.
MeyerR, SchönherrR, Gavrilova-RuchO, et al.Identification of Ether à Go-Go and calcium-activated potassium channels in human melanoma cells. J Membr Biol, 1999; 171:107–115.
122.
WulffH, CastleNA. Therapeutic potential of KCa3.1 blockers: Recent advances and promising trends. Expert Rev Clin Pharmacol, 2010; 3:385–396.
123.
BlochM, OusingsawatJ, SimonR, et al.KCNMA1 gene amplification promotes tumor cell proliferation in human prostate cancer. Oncogene, 2007; 26:2525–2534.
124.
BrevetM, FucksD, ChatelainD, et al.Deregulation of 2 potassium channels in pancreas adenocarcinomas: Implication of KV1.3 gene promoter methylation. Pancreas, 2009; 38:649–654.
125.
Alvarez-BaronCP, JonssonP, ThomasC, et al.The two-pore domain potassium channel KCNK5: Induction by estrogen receptor α and role in proliferation of breast cancer cells. Mol Endocrinol, 2011; 25:1326–1336.
126.
VoloshynaI, BesanaA, CastilloM, et al.TREK-1 is a novel molecular target in prostate cancer. Cancer Res, 2008; 68:4.
127.
LaskowskiM, AugustynekB, KulawiakB, et al.What do we not know about mitochondrial potassium channels?. Biochim Biophys Acta, 2016; 1857:1247–1257.
128.
HaradaN, InagakiN. Role of sodium-glucose transporters in glucose uptake of the intestine and kidney. J Diabetes Invest, 2012; 3:352–353.
129.
ScafoglioC, HirayamaBA, KepeV, et al.Functional expression of sodium-glucose transporters in cancer. PNAS, 2015; 112:E4111–E4119.
130.
Sotelo-HitschfeldT, NiemeyerMI, MächlerP, et al.Channel-mediated lactate release by K+-stimulated astrocytes. J Neurosci, 2015; 35:4168–4178.
131.
KucheryavykhYV, KucheryavykhLY, NicholsCG, et al.Downregulation of Kir4.1 inward rectifying potassium channel subunits by RNAi impairs potassium transfer and glutamate uptake by cultured cortical astrocytes. GLIA, 2007; 55:274–281.
132.
Yanyan LiY, Peili WangP, Jianchao XuJ, et al.Voltage-gated potassium channel Kv1.3 regulates GLUT4 trafficking to the plasma membrane via a Ca2+-dependent mechanism. Am J Physiol Cell Physiol, 2006; 290:C345–C351.
133.
MichelakisED, WebsterL, MackeyJR. Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer. Br J Cancer, 2008; 99:989–994.
134.
SunRC, FadiaM, DahlstromJE. Reversal of the glycolytic phenotype by dichloroacetate inhibits metastatic breast cancer cell growth in vitro and in vivo. Breast Cancer Res Treat, 2010; 120:253–260.
135.
XieJ, WangBS, YuD, et al.Dichloroacetate shifts the metabolism from glycolysis to glucose oxidation and exhibits synergistic growth inhibition with cisplatin in HeLa cells. In J Oncol, 2011; 38:2.
136.
HonasogeA, SontheimerH. Involvement of tumor acidification in brain cancer pathophysiology. Front Physiol, 2013; 4:316.
137.
López-BarneoJ, López-LópezJR, UreñaJ, et al.Chemotransduction in the carotid body: K+ current modulated by PO2 in type I chemoreceptor cells. Science, 1988; 241:580–582.
138.
ShimodaLA, PolakJ. Hypoxia. 4. Hypoxia and ion channel function. Am J Physiol Cell Physiol, 2011; 300:C951–C967.
139.
SetaKA, YuanY, SpicerZ, et al.The role of calcium in hypoxia-induced signal transduction and gene expression. Cell Calcium, 2004; 36:331–340.
140.
HuiAS, BauerAL, StrietJB, et al.Calcium signaling stimulates translation of HIF-alpha during hypoxia. FASEB J, 2006; 20:466–475.
141.
TajimaN, SchönherrK, NiedlingS, et al.Ca2+-activated K+ channels in human melanoma cells are up-regulated by hypoxia involving hypoxia-inducible factor-1alpha and the von Hippel-Lindau protein. J Physiol, 2006; 571(Pt 2):349–359.
142.
LaiQ, WangT, GuoQ, et al.Positive correlation between the expression of hEag1 and HIF-1α in breast cancers: An observational study. BMJ Open, 2014; 4:e005049.
143.
MuD, ChenL, ZhangX, et al.Genomic amplification and oncogenic properties of the KCNK9 potassium channel gene. Cancer Cell, 2003; 3:297–302.
144.
LeithnerK, HirschmuglB, LiY, et al.TASK-1 regulates apoptosis and proliferation in a subset of non-small cell lung cancers. PLoS One, 2016; 11:e0157453.
145.
GuXQ, PamenterME, SiemenD, et al.Mitochondrial but not plasmalemmal BK channels are hypoxia-sensitive in human glioma. GLIA, 2014; 62:504–513.
146.
SongM. Kv3.1 and Kv3.4 as tumor hypoxia related voltage-gated potassium channels. FASEB J, 2017; 31(1 Suppl): 934.4–934.42017.
147.
KempPJ, PeersC, MillerP, et al.Oxygen Sensing by Human Recombinant Tandem-P Domain Potassium Channels. In: PequignotJM, GonzalezC, NurseCA, PrabhakarNR, DalmazY, eds. Chemoreception (Advances in Experimental Medicine and Biology). Boston, MA: Springer, 2003:536.
148.
DjamgozMB, RustemO. Persistent current blockers of voltage-gated sodium channels: A clinical opportunity for controlling metastatic disease. Recent Pat Anticancer Drug Discov, 2013; 8:66–84.
149.
BondaravaM, LiT, EndlE, et al.Epub 2009 Feb 25.alpha-ENaC is a functional element of the hypertonicity-induced cation channel in HepG2 cells and it mediates proliferation. Pflugers Arch, 2009; 458:675–687.
150.
ZhangX, SooriG, DoblemanTJ, et al.The application of monoclonal antibodies in cancer diagnosis. Expert Rev Mol Diagn, 2014; 14:97–106.
151.
ScottAM, AllisonJP, WolchokJD, Monoclonal antibodies in cancer therapy. Cancer Immun, 2012; 12:14.
152.
BecchettiA, CrescioliS, ZanieriF, et al.The conformational state of hERG1 channels determines integrin association, downstream signaling, and cancer progression. Sci Signal, 2017; 10:eaaf3236.
153.
IorioJ, D'AmicoM, Arcangeli. Functional relationships between ion channels and pH-regulating mechanisms in colorectal cancer. In: 4thAnnual Meeting of the International Society of Cancer Metabolism. 2017: Oral presentation. 19.
